ASCVD, Atherosclerotic Cardiovascular Disease, Cancer, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Conditions
Keywords
ASCVD, cancer, PCSK9
Brief summary
This study is a prospective, randomized, open-label, and single center trial. To evaluate the effect of treatment with PCSK9 inhibitor on the risk for cardiovascular death, recurrent unstable angina, myocardial infarction, stroke, or coronary revascularization in patients with very high risk of atherosclerotic cardiovascular disease (ASCVD) and cancer.
Detailed description
Subjects will be randomly assigned in a 1:1 ratio to receive subcutaneous injections of PCSK9 inhibitor (evolocumab:420 mg every 4 weeks) plus moderate intensity statin therapy or the statin alone therapy. After randomization, patients will come to the hospital every 4 weeks to collect relevant laboratory results and clinical outcomes, and be detected by echocardiography and carotid ultrasound every 12 weeks until the end of follow-up at week 48 or the occurrence of an endpoint event. The entire study is expected to be conducted for 3 years, with a recruitment period of 2 years.
Interventions
DRUGEvolocumab
Evolocuma:420 mg every 4 weeks
DRUGStatin
The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).
Sponsors
Xinjiang Medical University
Xiang Xie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Intervention model description
patients with very high risk of ASCVD and cancer
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Male or female ≥ 18 to ≤ 80 years of age * Patients with very high risk of ASCVD (with any of the following): 1. Documented ASCVD, either clinical or unequivocal on imaging. Documented ASCVD includes previous acute coronary syndrome (ACS), stable angina, coronary revascularization (percutaneous coronary intervention, coronary artery bypass graft, and other arterial revascularization procedures), stroke and transient ischemic attack (TIA), and peripheral arterial disease. Unequivocally documented ASCVD on imaging includes those findings that are known to be predictive of clinical events, such as significant plaque on coronary angiography or computed tomography (CT) scan (multivessel coronary disease with two major epicardial arteries having \>50% stenosis), or on carotid ultrasound. 2. Diabetes mellitus (DM) with target organ damage, or at least three major risk factors, or early onset of type 1 diabetes mellitus (T1DM) of long duration (\>20 years). * Patients have been diagnosed with cancer through histopathology and have a life expectancy of more than 1 year * Fasting low-density lipoprotein cholesterol (LDL-C) ≥ 1.8 mmol/L or non-high-density lipoprotein cholesterol (non HDL-C) \> 2.6 mmol/L * Participate voluntarily and sign an informed consent * Negative serum Pregnancy test (in women with fertility potential)
Exclusion criteria
* Pregnant and lactating women * During the study period and within 3 months of receiving the last dose of the study drug, women with fertility intentions and men unwilling to use effective contraceptive methods * New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction \< 30% * Uncontrolled hypertension, defined as systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg * Plan for coronary revascularization or other cardiac surgery in recent (within 3 months after randomization) * Severe renal insufficiency, defined as estimated glomerular filtration rate (eGRF) \< 30ml/min/1.73m2 or Serum creatinine (Scr) \> 221 umol/L * Severe liver dysfunction, defined as an increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 3 times above the upper limit of normal * Have used PCSK9 inhibitors within 3 months before enrollment, or have a history of severe allergic reactions to PCSK9 inhibitors * Severe infections requiring intravenous antibiotics * HIV-positive or history of acquired immunodeficiency syndrome (AIDS) * With cognitive impairment or psychiatric illnesses * Participating in other trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major cardiovascular adverse events | From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks | Major cardiovascular adverse events include cardiovascular death, recurrent unstable angina, myocardial infarction, stroke, and coronary revascularization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All cause death | From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks | All cause death |
| Composite end points | From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks | Composite end points include cardiogenic shock, cardiac arrest, malignant arrhythmia, heart failure, Non-coronary revascularization |
| The compliance rate of lipid control | From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks | Main indicator: LDL-C decreased to below 1.4 mmol/L and decreased by more than 50% from baseline; secondary indicator: non HDL-C\<2.2 mmol/L; |
| The changes of carotid plaque | From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks | By carotid ultrasound |
Contacts
Primary ContactXiang Xie, PhD
Outcome results
None listed